论文部分内容阅读
近年来钙离子拮抗剂——心痛定,应用于治疗高血压受到重视,但含服心痛定治疗肾性高血压尚未见报告.为了探讨心痛定在治疗肾性高血压方面的价值,我院试用心痛定舌下含服治疗肾性高血压39例,并对用药后不同时间的血压变化作了动态观察,取得了较满意疗效,现报告如下.临床资料病例选择:受试者系我院1985年5月至1986年11月住院的肾性高血压患者共39例(其中慢性肾小球肾炎28例,慢性肾盂肾炎1例,狼疮性肾炎3例,尿毒症7例,先天性多囊肾1例).男23,女6例,年龄15～56岁,平均31岁。观察方法:血压中、重度升高(BP≥180/110或收缩压>200或舒张压>120)者为Ⅰ组,共21例,
In recent years, calcium antagonist - nifedipine, used in the treatment of high blood pressure attention, but no convinced of the treatment of renal hypertension have been reported .In order to explore the value of nifedipine in the treatment of renal hypertension, our hospital trial Heartache given sublingual suppository treatment of 39 cases of renal hypertension, and changes in blood pressure at different times after treatment made a dynamic observation, and achieved satisfactory results, are as follows.Clinical data Case selection: Subjects in our hospital 1985 May 1999 to November 1986 hospitalized patients with hypertension in 39 cases (including 28 cases of chronic glomerulonephritis, chronic pyelonephritis in 1 case, 3 cases of lupus nephritis, uremia in 7 cases, congenital polycystic kidney disease 1 case) .Men 23, 6 females, aged 15 to 56 years old, average 31 years old. Observation methods: blood pressure, severe increase (BP≥180 / 110 or systolic blood pressure> 200 or diastolic blood pressure> 120) for the group Ⅰ, a total of 21 cases,